Direct Bilirubin, but not Indirect Bilirubin, is Associated with Short-term Adverse Events in HFpEF

Sunying Wang; Yan Chen; Hanghao Ma; Yuwei Wang; Manqing Luo; Xianwei Xie; Qingyong Yang; Kaijin Lin; Meihua Lin; Lin Lin; Ping Chen; Qiaowen Zheng; Fuqing Sun

doi:10.2174/0115665232273115240102043640

Direct Bilirubin, but not Indirect Bilirubin, is Associated with Short-term Adverse Events in HFpEF

Authors: Wang S.¹, Chen Y.², Ma H.³, Wang Y.⁴, Luo M.⁵, Xie X.⁶, Yang Q.⁷, Lin K.¹, Lin M.¹, Lin L.¹, Chen P.¹, Zheng Q.¹, Sun F.¹
Affiliations:
1. , Fuqing City Hospital Affiliated to Fujian Medical University
2. Department of Ultrasound, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University
3. , Ningde People's Hospital
4. Department of Management, Fujian Yirong Information Technology Corporation
5. Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
6. Department of Cardiology, Fujian Provincial Hospital
7. Department of Internal Medicine, Jinshan Branch of Fujian Provincial Hospital
Issue: Vol 24, No 4 (2024)
Pages: 321-330
Section: Life Sciences
URL: https://rjmseer.com/1566-5232/article/view/644038
DOI: https://doi.org/10.2174/0115665232273115240102043640
ID: 644038

Cite item

Full Text

Abstract

Objective:Abnormal live function tests have been identified as independent risk factors for ominous prognosis in patients with heart failure. However, most of the previous studies have failed to determine the contribution of direct bilirubin (DBIL) and indirect bilirubin (IBIL) separately. Hence, we aimed to explore whether DBIL or IBIL is correlated with the prognosis of heart failure with preserved ejection fraction (HFpEF).

Methods:A total of 19837 patients were hospitalized for HFpEF between January 2012 and January 2022 in Fuqing City Hospital affiliated with Fujian Medical University. The primary endpoint was in-hospital all-cause mortality. Secondary endpoints included in-hospital cardiovascular mortality and 30-day re-admission for heart failure.

Results:Univariable analysis indicated that patients with elevated DBIL or IBIL were exposed to a higher risk of mortality and re-admission. However, in multivariable models, both ln-transformed DBIL and TBIL, but not IBIL, were independent risk factors for in-hospital all-cause mortality [hazard ratio (HR)=1.796, 95% confidential interval (CI)=1.477-2.183, P＜0.001; HR=1.854, 95% CI=1.461-2.352, P＜0.001; HR=1.161, 95% CI=0.959-1.407, P=0.126] and in-hospital cardiovascular mortality (HR=1.831, 95% CI=1.345-2.492, P＜0.001; HR=1.899, 95% CI=1.300-2.773, P=0.001; HR=1.145, 95% CI=0.841-1.561, P=0.389). Only DBIL remained independently associated with 30-day readmission for heart failure (HR=1.361, 95% CI=1.036-1.787, P=0.027). Adding ln-transformed DBIL to model 1 increased its discriminatory capacity (C-statistic: 0.851 to 0.869, respectively), whereas adding ln-transformed IBIL yielded little increment (C-statistic: 0.851 to 0.852, respectively).

Conclusion:DBIL, but not IBIL, was associated with short-term ominous prognosis in patients with HFpEF. Hence, DBIL may be the superior predictor for prognosis in HFpEF.

Keywords

Heart failure with preserved ejection fraction, direct bilirubin, indirect bilirubin, prognosis, mortality, readmission.

References

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016; 37(27): 2129-200. doi: 10.1093/eurheartj/ehw128 PMID: 27206819
Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355(3): 251-9. doi: 10.1056/NEJMoa052256 PMID: 16855265
Suzuki K, Claggett B, Minamisawa M, et al. Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. Eur J Heart Fail 2020; 22(9): 1662-71. doi: 10.1002/ejhf.1853 PMID: 32407608
Samsky MD, Dunning A, DeVore AD, et al. Liver function tests in patients with acute heart failure and associated outcomes: Insights from ASCEND‐HF. Eur J Heart Fail 2016; 18(4): 424-32. doi: 10.1002/ejhf.440 PMID: 26707029
Yokoyama M, Watanabe T, Otaki Y, et al. Associatowion of the aspartate aminotransferase to alanine aminotransferase ratio with bnp level and cardiovascular mortality in the general population: The yamagata study 10-year foll-Up. Dis Markers 2016; 2016: 1-9. doi: 10.1155/2016/4857917 PMID: 27872510
Allen LA, Felker GM, Pocock S, et al. Liver function abnormalities and outcome in patients with chronic heart failure: Data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 2009; 11(2): 170-7. doi: 10.1093/eurjhf/hfn031 PMID: 19168515
Liang W, He X, Wu D, et al. Prognostic implication of liver function tests in heart failure with preserved ejection fraction without chronic hepatic diseases: Insight from TOPCAT trial. Front Cardiovasc Med 2021; 8: 618816. doi: 10.3389/fcvm.2021.618816 PMID: 34055924
Prenner SB, Kumar A, Zhao L, et al. Effect of serum albumin levels in patients with heart failure with preserved ejection fraction (from the TOPCAT Trial). Am J Cardiol 2020; 125(4): 575-82. doi: 10.1016/j.amjcard.2019.11.006 PMID: 31843232
Sundaram V, Fang JC. Gastrointestinal and liver issues in heart failure. Circulation 2016; 133(17): 1696-703. doi: 10.1161/CIRCULATIONAHA.115.020894 PMID: 27143152
Çağlı K, Başar FN, Tok D, Turak O, Başar O. How to interpret liver function tests in heart failure patients? Turk J Gastroenterol 2020; 26(3): 197-203. doi: 10.5152/tjg.2015.0086 PMID: 26006191
Wang S, Wang Y, Luo M, et al. MELD-XI score is associated with short-term adverse events in patients with heart failure with preserved ejection. Front Cardiovasc Med 2021; 8: 650191. doi: 10.3389/fcvm.2021.650191 PMID: 34113661
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42(36): 3599-726. doi: 10.1093/eurheartj/ehab368 PMID: 34447992
Wu AH, Levy WC, Welch KB, et al. Association between bilirubin and mode of death in severe systolic heart failure. Am J Cardiol 2013; 111(8): 1192-7. doi: 10.1016/j.amjcard.2012.12.048 PMID: 23351460
Shiomura R, Kobayashi N, Shirakabe A, et al. Systolic blood pressure and cardiac mortality related to serum total bilirubin levels at admission in patients with acute heart failure. Heart Vessels 2021; 36(1): 69-75. doi: 10.1007/s00380-020-01666-1 PMID: 32671462
Zheng H, Li Y, Xie N. Association of serum total bilirubin levels with diastolic dysfunction in heart failure with preserved ejection fraction. Biol Res 2014; 47(1): 7. doi: 10.1186/0717-6287-47-7 PMID: 25027460
van Deursen VM, Edwards C, Cotter G, et al. Liver function, in-hospital, and post-discharge clinical outcome in patients with acute heart failure-results from the relaxin for the treatment of patients with acute heart failure study. J Card Fail 2014; 20(6): 407-13. doi: 10.1016/j.cardfail.2014.03.003 PMID: 24642379
Guan B, Yang M, Shen X, et al. Genetically determined serum bilirubin level and the risk of heart failure: A mendelian randomization study. Front Genet 2023; 14: 1067146. doi: 10.3389/fgene.2023.1067146 PMID: 36713081
Okada A, Sugano Y, Nagai T, et al. Usefulness of the direct and/or total bilirubin to predict adverse outcomes in patients with acute decompensated heart failure. Am J Cardiol 2017; 119(12): 2035-41. doi: 10.1016/j.amjcard.2017.03.033 PMID: 28456315
Durante-Mangoni E, Parrella A, Pafundi PC, et al. Liver histopathological findings in advanced heart failure: A reappraisal of cardiac cirrhosis concept. Intern Emerg Med 2019; 14(6): 931-40. doi: 10.1007/s11739-019-02033-3 PMID: 30689135
Kato T, Niizuma S, Inuzuka Y, et al. Analysis of liver metabolism in a rat model of heart failure. Int J Cardiol 2012; 161(3): 130-6. doi: 10.1016/j.ijcard.2011.07.056 PMID: 21839528
Yoshihisa A, Sato Y, Yokokawa T, et al. Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction. ESC Heart Fail 2018; 5(2): 262-70. doi: 10.1002/ehf2.12222 PMID: 28967709

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

Direct Bilirubin, but not Indirect Bilirubin, is Associated with Short-term Adverse Events in HFpEF

Full Text

Abstract

Keywords

About the authors

References

Supplementary files